A detailed history of Syntax Advisors, LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Syntax Advisors, LLC holds 1,558 shares of ABBV stock, worth $257,054. This represents 0.4% of its overall portfolio holdings.

Number of Shares
1,558
Previous 1,667 6.54%
Holding current value
$257,054
Previous $224,000 3.57%
% of portfolio
0.4%
Previous 0.35%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 13, 2023

SELL
$133.59 - $154.65 $14,561 - $16,856
-109 Reduced 6.54%
1,558 $232,000
Q2 2023

Aug 14, 2023

BUY
$132.51 - $164.9 $8,878 - $11,048
67 Added 4.19%
1,667 $224,000
Q1 2023

May 15, 2023

BUY
$144.61 - $166.54 $16,485 - $18,985
114 Added 7.67%
1,600 $254,000
Q4 2022

Feb 14, 2023

SELL
$138.31 - $165.87 $45,918 - $55,068
-332 Reduced 18.26%
1,486 $240,000
Q3 2022

Nov 14, 2022

BUY
$134.21 - $153.93 $19,326 - $22,165
144 Added 8.6%
1,818 $244,000
Q2 2022

Aug 12, 2022

BUY
$137.62 - $174.96 $18,578 - $23,619
135 Added 8.77%
1,674 $256,000
Q1 2022

May 11, 2022

SELL
$131.98 - $163.75 $70,345 - $87,278
-533 Reduced 25.72%
1,539 $249,000
Q4 2021

Feb 14, 2022

BUY
$107.43 - $135.93 $222,594 - $281,646
2,072 New
2,072 $281,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $292B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Syntax Advisors, LLC Portfolio

Follow Syntax Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Syntax Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Syntax Advisors, LLC with notifications on news.